As many know too well, there is not much doctors can do for patients with malignant pleural mesothelioma. This is not say there aren’t a multitude of FDA-approved treatment options, because there are, but even in the best case scenarios, patients undergo invasive and painful procedures and may only be given an extra few months to live.
There is, however, hope that, one day, there will be real treatment options for mesothelioma patients that can actually arrest the growth of tumors or even force them into remission. One drug that people thought might help doctors and patients achieve these goals was known as VS-6063, being developed by Verestem Inc. pharmaceuticals based in Cambridge, Massachusetts. The company had recruited patients with malignant pleural mesothelioma in 2011, and, by 2012, the company had announced it was closing enrollment in the study because it had enough patients with the deadly disease to complete the study. Continue reading